201 related articles for article (PubMed ID: 25973019)
1. β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.
Jing X; Zhang H; Hu J; Su P; Zhang W; Jia M; Cheng H; Li W; Zhou G
Int J Clin Exp Pathol; 2015; 8(2):1354-63. PubMed ID: 25973019
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
3. [Experimental study of adenovirus-mediated p53 gene on the reversal of multidrug resistance in breast cancer].
He SZ; Qi XD; Zhang XM; Wang Y
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2935-7. PubMed ID: 18261311
[TBL] [Abstract][Full Text] [Related]
4. Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors.
Shao SL; Zhang WW; Li XY; Zhang ZZ; Yun DZ; Fu B; Zuo MX
Cancer Biother Radiopharm; 2010 Apr; 25(2):171-7. PubMed ID: 20423230
[TBL] [Abstract][Full Text] [Related]
5. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
6. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
7. [Effects of schisandrin B on reversing multidrug resistance in human breast cancer cells transfected with mdr1 gene].
Li L; Wang T; Xu ZL; Yu Y; Chen W; Chen F
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1633-7. PubMed ID: 16185533
[TBL] [Abstract][Full Text] [Related]
8. [Significance and reversal of MDR1/P-gp in pancreatic cancer chemotherapy].
Guo JC; Zhao YP; Liao Q; Zhu Y
Zhonghua Wai Ke Za Zhi; 2007 Nov; 45(21):1488-90. PubMed ID: 18275717
[TBL] [Abstract][Full Text] [Related]
9. Determining MDR1/P-glycoprotein expression in breast cancer.
Faneyte IF; Kristel PM; van de Vijver MJ
Int J Cancer; 2001 Jul; 93(1):114-22. PubMed ID: 11391630
[TBL] [Abstract][Full Text] [Related]
10. Drug resistant breast cancer cells overexpress ETS1 gene.
Kars MD; Işeri OD; Gündüz U
Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
[TBL] [Abstract][Full Text] [Related]
11. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
13. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells.
Wang Y; Ma G; Wang Q; Wen M; Xu Y; He X; Zhang P; Wang Y; Yang T; Zhan P; Wei G
Molecules; 2013 Dec; 19(1):159-76. PubMed ID: 24368600
[TBL] [Abstract][Full Text] [Related]
14. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
15. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.
Wu H; Hait WN; Yang JM
Cancer Res; 2003 Apr; 63(7):1515-9. PubMed ID: 12670898
[TBL] [Abstract][Full Text] [Related]
17. EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
Jin Y; Zhang W; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Oncol Rep; 2016 Feb; 35(2):771-8. PubMed ID: 26718028
[TBL] [Abstract][Full Text] [Related]
18. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
Trock BJ; Leonessa F; Clarke R
J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
